{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:40:09Z","timestamp":1756276809713,"version":"3.44.0"},"reference-count":15,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2025,7]]},"abstract":"Abstract<\/jats:title>\n \n Commentary on:<\/jats:bold> Lafayette R, Kristensen J, Stone A, et al<\/jats:italic>. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet<\/jats:italic>. 2023;402:859\u201370.<\/jats:p>\n \n Series co-ordinator:<\/jats:bold> Dr Teck Khong, DTB Associate Editor, Clinical Pharmacology, St George\u2019s, University of London, UK<\/jats:p>","DOI":"10.1136\/dtb.2024.000071","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:20:12Z","timestamp":1744723212000},"page":"100-102","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted-release budesonide for patients with IgA nephropathy"],"prefix":"10.1136","volume":"63","clinical-trial-number":[{"clinical-trial-number":"nct03643965","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Isaac","family":"Chung","sequence":"first","affiliation":[{"name":"Blood Pressure Unit, St George\u2019s University Hospitals NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9873-1204","authenticated-orcid":false,"given":"Teck K","family":"Khong","sequence":"additional","affiliation":[{"name":"Blood Pressure Unit, St George\u2019s University Hospitals NHS Trust, London, UK"},{"name":"Clinical Pharmacology, St George\u2019s University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2025082623130991000_63.7.100.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01554-4"},{"key":"2025082623130991000_63.7.100.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1206793"},{"key":"2025082623130991000_63.7.100.3","unstructured":"Rout P , Limaiem F , Hashmi MF . IgA nephropathy (Berger disease) [online]. 2024. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538214\/ [Accessed Mar 2025]."},{"key":"2025082623130991000_63.7.100.4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1436923","article-title":"Contemporary review of IgA nephropathy","volume":"15","author":"Filippone","year":"2024","journal-title":"Front Immunol"},{"key":"2025082623130991000_63.7.100.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415463"},{"key":"2025082623130991000_63.7.100.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9362"},{"key":"2025082623130991000_63.7.100.7","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.0000000000000135"},{"key":"2025082623130991000_63.7.100.8","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.2147\/DDDT.S383138","article-title":"Insights on Nefecon, a Targeted-Release Formulation of Budesonide and Its Selective Immunomodulatory Effects in Patients with IgA Nephropathy","volume":"18","author":"Barratt","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"2025082623130991000_63.7.100.9","unstructured":"Kinpeygo 4 mg modified release hard capsules. Summary of Product Characteristics, GB. Genus Pharmaceuticals Holdings Ltd; December 2023."},{"key":"2025082623130991000_63.7.100.10","unstructured":"European Medicines Agency . Kinpeygo [online]. 2024. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kinpeygo [Accessed 18 Mar 2025]."},{"key":"2025082623130991000_63.7.100.11","unstructured":"Center for Drug Evaluation and Research . Approval package for 215935orig1s000 [online]. 2021. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/215935Orig1s000Approv.pdf [Accessed Mar 2025]."},{"key":"2025082623130991000_63.7.100.12","unstructured":"National Institute for Health and Care Excellence . Targeted-release budesonide for treating primary IgA nephropathy (TA937) [online]. 2023. Available: https:\/\/www.nice.org.uk\/guidance\/ta937 [Accessed 18 Mar 2025]."},{"key":"2025082623130991000_63.7.100.13","unstructured":"Joint Formulary Committee . British National Formulary [online]. 2025. Available: https:\/\/bnf.nice.org.uk [Accessed 18 Mar 2025]."},{"key":"2025082623130991000_63.7.100.14","doi-asserted-by":"crossref","first-page":"20119","DOI":"10.1038\/s41598-023-47393-1","article-title":"An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression","volume":"13","author":"Obri\u0219c\u0103","year":"2023","journal-title":"Sci Rep"},{"key":"2025082623130991000_63.7.100.15","unstructured":"Budenofalk 3mg gastro-resistant capsules. Summary of Product Characteristics, UK. Dr Falk Pharma GmbHR; December 2019."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2024.000071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:13:22Z","timestamp":1756275202000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2024.000071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,6,30]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/dtb.2024.000071"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2024.000071","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2025,4,15]]}}}